<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03397706</url>
  </required_header>
  <id_info>
    <org_study_id>VT3996-201</org_study_id>
    <nct_id>NCT03397706</nct_id>
  </id_info>
  <brief_title>Dose Escalation &amp; Expansion Study of Oral VRx-3996 &amp; Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies</brief_title>
  <official_title>A Phase 1b/2 Open-Label, Dose Escalation &amp; Expansion Study of Orally Administered VRx-3996 &amp; Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viracta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viracta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination
      with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in
      relapsed/refractory EBV+ lymphomas.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether VRx-3996 in combination with valganciclovir
      is safe, determine the side effect profile, and to determine whether this therapy may help
      patients with EBV-related lymphomas. The study has two phases. Goals of the first phase
      include determining a safe and tolerable dose that can be administered in phase 2. Goals of
      the second phase include further evaluating the safety and tolerability of VRx-3996 in
      combination with valganciclovir, evaluating how the drugs are metabolized in the body,
      evaluating response rates and other exploratory objectives that will help the researchers
      evaluate how these drugs work in the body. Participants will receive daily oral doses of the
      two study drugs and will have multiple study visits where they will have blood collected,
      physical examinations, and other medical monitoring.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2018</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase 1: dose escalation phase (3+3 design with definitions of dose limiting toxicity) to define a recommended phase 2 dose
Phase 2: dose expansion</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events and changes in clinical safety laboratory values in Dose Escalation and Cohort Expansion</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Determination of a safe and tolerable Recommended Phase 2 Dose (RP2D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities in in Dose Escalation and Cohort Expansion</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Determine safety and tolerability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR as measured by stable disease (SD), partial response (PR), and complete response (CR) by radiographic assessment</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Disease response will be assessed using a combination of physical exam and imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single-dose and steady-state Cmax of VRx-3996 and valganciclovir</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>PK assessment of both VRx-3996 and valganciclovir at 0, 1, 1.5, 2, 3, 5 and 7 hours post-dose on C1D1 and pre-dose on Day 1 of all following cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single-dose and steady-state AUC of VRx-3996 and valganciclovir</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>PK assessment of both VRx-3996 and valganciclovir at 0, 1, 1.5, 2, 3, 5 and 7 hours post-dose on C1D1 and pre-dose on Day 1 of all following cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state Elimination half-life of VRx-3996 and valganciclovir</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>PK assessment of both VRx-3996 and valganciclovir at 0, 1, 1.5, 2, 3, 5 and 7 hours post-dose on C1D1 and pre-dose on Day 1 of all following cycles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>The time from the start of first study drug administration to the first overall tumor response observed for subjects who achieved a CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>The time interval (days) from date of the first overall response (CR or PR; achieved after the study drug administration) to the date of disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to approximately 2 years</time_frame>
    <description>The interval between the date of first study drug administration and the date of PD or death, whichever is first reported</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Epstein-Barr Virus Associated Lymphoma</condition>
  <condition>Lymphoproliferative Disorders</condition>
  <arm_group>
    <arm_group_label>Phase 1b Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VRx-3996 (cohort 1) and valganciclovir
VRx-3996 (cohort 2) and valganciclovir
VRx-3996 (cohort 3) and valganciclovir
VRx-3996 (cohort 4) and valganciclovir
VRx-3996 (cohort 5) and valganciclovir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VRx-3996 (RP2D: recommended phase 2 dose) and valganciclovir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VRx-3996</intervention_name>
    <description>capsules taken orally once or twice daily</description>
    <arm_group_label>Phase 1b Dose Escalation</arm_group_label>
    <arm_group_label>Phase 2 Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>tablets taken orally once or twice daily</description>
    <arm_group_label>Phase 1b Dose Escalation</arm_group_label>
    <arm_group_label>Phase 2 Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Relapsed/refractory, pathologically confirmed EBV+ lymphoid malignancy or
             lymphoproliferative disease

          -  Absence of available therapy with reasonable likelihood of cure or significant
             clinical benefit

          -  Adequate hematologic, hepatic and renal function as defined by laboratory assessment

        Key Exclusion Criteria:

          -  Known primary CNS lymphoma

          -  Known CNS metastases or leptomeningeal disease unless appropriately treated and
             neurologically stable for at least 4 weeks

          -  Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic
             therapy

          -  Refractory graft versus host disease (GvHD) not responding to treatment

          -  Known active hepatitis B virus infection

          -  Circulating hepatitis C virus on qPCR
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marshelle Warren, MD, Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Viracta Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert McRae, Sr. Director, R&amp;D Operations</last_name>
    <phone>858-400-8470</phone>
    <email>ClinicalTrials@Viracta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Irvine Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Perez</last_name>
      <phone>714-509-2414</phone>
      <email>michelrp@uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Massingill</last_name>
      <phone>720-848-0736</phone>
      <email>Justin.Massingill@ucdenver.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Crystal Durden</last_name>
      <phone>706-721-0660</phone>
      <email>CRDurden@augusta.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruth M Rothstein CORE Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mieoak Bahk</last_name>
      <phone>312-572-4543</phone>
      <email>mbahk@cookcountyhhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplantation</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Coleman</last_name>
      <phone>317-528-7298</phone>
      <email>melanie.coleman@franciscanalliance.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Wood</last_name>
      <phone>313-916-7827</phone>
      <email>mwood5@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack UMC</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Kdiry</last_name>
      <phone>551-996-5952</phone>
      <email>Sabrina.Kdiry@hackensackmeridian.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center James Cancer Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Jenkins</last_name>
      <phone>614-366-0855</phone>
      <email>cynthia.jenkins@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariel Kobylak</last_name>
      <phone>215-955-2810</phone>
      <email>Ariel.Kobylak@jefferson.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lovlei McKinnie</last_name>
      <phone>215-214-3173</phone>
      <email>Lovlei.McKinnie@fccc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital do Cancer Mae de Deus</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.viracta.com/</url>
    <description>Viracta Therapeutics, Inc.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2018</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EBV+ post-transplant lymphoproliferative malignancy</keyword>
  <keyword>EBV-associated lymphoproliferative disorders associated with acquired immunodeficiency including HIV-positive</keyword>
  <keyword>Relapsed, refractory, EBV+ lymphoid malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

